Articles about Adar Poonawalla

Billions need to be vaccinated at a faster rate to reach the end of the COVID-19 pandemic, said Adar Poonawalla, CEO of the Serum Institute of India (SII), which manufactures the COVID-19 vaccine Covishield.

The Serum Institute of India is looking to launch a COVID-19 vaccine for children in six months, SII CEO Adar Poonawalla said Tuesday.

The European Medicines Agency (EMA) said it has not received any application for the authorization of the coronavirus vaccine Covishield.

The Serum Institute of India (SII) will soon apply for regulatory approval to conduct clinical trials of Covovax on children in India.

The Serum Institute of India (SII) is looking to launch the COVID-19 vaccine developed by the United States firm Novavax in India by September.

The Union Health Ministry on Monday refuted media reports that claimed that the central government had not placed fresh orders for COVID-19 vaccines.

Serum Institute of India CEO Adar Poonawalla has revealed that his decision to fly to London when India is facing a COVID-19 second wave was largely due to the threats he had been facing.

Adar Poonawalla, the CEO of the Serum Institute of India (SII), on Wednesday announced that the price of the COVID-19 vaccine Covishield was being reduced from Rs. 400 to Rs. 300 for states.

As India faces a record surge in coronavirus infections, Serum Institute of India (SII) CEO Adar Poonawalla has raised concerns about the United States and Europe holding back key vaccine raw material.

Serum Institute of India (SII), the manufacturer of the coronavirus vaccine Covishield, has been served a legal notice by the drug maker AstraZeneca over delays in vaccine supply, the company's CEO Adar Poonawalla confirmed in an interview earlier this week.

The efficacy of the COVID-19 vaccine Covishield could increase to 90% if the two doses are given 2.5-3 months apart, Serum Institute of India CEO Adar Poonawalla said Monday.

Serum Institute of India CEO Adar Poonawalla today said that his company hopes to launch its second coronavirus vaccine by September this year.

Adar Poonawalla, the head of the world's biggest vaccine maker, and the World Health Organization's (WHO) chief scientist have said that the manufacturers of coronavirus vaccine doses are facing a global shortage of the raw materials required to produce the doses.

Thursday's fire at Pune's Serum Institute of India will impact the production of BCG and rotavirus vaccines in the future, the company said on Friday.

The Maharashtra government has ordered a probe into the fire that broke out at the Serum Institute of India in Pune on Thursday, killing at least five people.

On Thursday afternoon, a fire broke out at the Terminal 1 gate of Serum Institute of India, Pune.

The Pune-based Serum Institute of India (SII) has received the purchase order for COVID-19 vaccines from the central government, officials said on Monday.

On Thursday night, the Pune Airport was prepared to airlift vials of coronavirus vaccine, the first such exercise in India's massive inoculation drive.

The first dose of the coronavirus vaccine in India will most likely be administered on January 13, a statement from a top official of the Union Health Ministry indicated on Tuesday.

The Serum Institute of India (SII) and Bharat Biotech have taken a joint pledge to ensure global access of the COVID-19 vaccines developed by them.

While the Indian government has prioritized healthcare workers and high-risk individuals in its vaccine program, doses of the coronavirus vaccine will be available for private companies, hospitals, and individuals by as early as March, the CEO of Serum Institute of India (SII), Adar Poonawalla, said on Sunday.

Serum Institute of India's (SII) chief Adar Poonawalla today wished everyone a happy new year along with a great announcement.

Earlier on Sunday, the Drugs Controller General of India (DCGI) announced the issuance of emergency approval to two COVID-19 vaccines for restricted use in India: Covishield and COVAXIN.

In a development that will soothe the coronavirus-battered nation, the Central Drugs Standard Control Organization (CDSCO) panel on Friday gave approval to the vaccine developed by the University of Oxford and British-pharma giant AstraZeneca.

The Ministry of Home Affairs on Monday extended guidelines for COVID-19 surveillance, containment, and caution till January 31, 2021.

Prime Minister Narendra Modi is set to chair an all-party meeting this Friday to review the COVID-19 situation in India, according to reports.

The CEO of the Serum Institute of India (SII), Adar Poonawalla, on Saturday said that the company will seek the emergency-use authorization of the coronavirus vaccine 'Covishield' soon.

Prime Minister Narendra Modi will visit three cities today to review the coronavirus vaccine development and manufacturing process, his office revealed.

The CEO of the Serum Institute of India (SII), Adar Poonawalla, has said that the institute can roll out 100 million doses of the COVID-19 vaccine by January-February.

Pune-based Serum Institute of India, which has partnered with Oxford University and British pharma giant AstraZeneca, plans to seek an emergency approval from the government of India next month, for providing the coronavirus vaccine to "corona warriors" and the elderly.

The Serum Institute of India is hoping to produce 100 million (10 crore) doses of AstraZeneca and Oxford University's COVID-19 vaccine, CEO Adar Poonawalla said.

The Indian Council of Medical Research (ICMR) and Pune-based Serum Institute of India (SII) on Thursday announced the completion of enrollment of participants to the Phase-3 clinical trials for the potential COVID-19 vaccine COVISHIELD in India.

Even as the COVID-19 outbreak has witnessed a downward trend in India, some states have been reporting large spikes in infections, indicating that the pandemic is far from over.

The coronavirus vaccine being developed by Bharat Biotech could be launched by February, months earlier than expected, an official from the Indian Council of Medical Research (ICMR), told Reuters on Thursday.

Adar Poonawalla, the CEO of Serum Institute of India, said that the vaccine against coronavirus will be available in India by January 2021, two months from now, provided that the government gives approvals on time.

It has been almost a year since the coronavirus pandemic began, yet the virus is far from being brought under control.

In a welcome piece of development, Serum Institute of India's CEO Adar Poonawalla said on Wednesday that the coronavirus vaccine, being developed by Oxford University, could be available for use in India by December 2020.

The Indian government has reportedly set aside Rs. 50,000 crore to ensure that the COVID-19 vaccine reaches the entire country.

As the world's largest vaccine manufacturer, India will play a major role in the vaccination efforts for COVID-19.

As India's COVID-19 vaccine strategy becomes a point of debate, Adar Poonawalla has expressed confidence over Prime Minister Narendra Modi's vision to protect Indian citizens from the ongoing pandemic.